Nic G. Scalfarotto
Keine laufenden Positionen mehr
Profil
Nic G.
Scalfarotto held former positions as Vice President-Regulatory Affairs at Momenta Pharmaceuticals, Inc., Senior Vice President-Regulatory Affairs at Aegerion Pharmaceuticals, Inc. and Kura Oncology, Inc., and VP-Regulatory Affairs & Program Management at X4 Pharmaceuticals, Inc. He obtained an undergraduate degree from Seton Hall University and a doctorate degree from Alma Mater Studiorum - Università di Bologna.
Ehemalige bekannte Positionen von Nic G. Scalfarotto
| Unternehmen | Position | Ende |
|---|---|---|
| KURA ONCOLOGY, INC. | General Counsel | - |
| X4 PHARMACEUTICALS, INC. | General Counsel | - |
| AEGERION PHARMACEUTICALS, INC. | General Counsel | - |
| MOMENTA PHARMACEUTICALS, INC. | General Counsel | - |
Ausbildung von Nic G. Scalfarotto
| Seton Hall University | Undergraduate Degree |
| Alma Mater Studiorum - Università di Bologna | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
